GLP-1 & Incretin Science

What Is Semaglutide? Structure, Mechanism and Evidence

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Semaglutide is a peptide analogue of human GLP-1 sharing roughly 94% sequence homology with the native hormone. Three modifications give it a once-weekly half-life: an Aib substitution at position 8 that blocks DPP-4 cleavage, a C18 diacid chain that binds albumin, and an Arg34Lys substitution. It is marketed as Ozempic, Wegovy and Rybelsus.

Key facts

Class
GLP-1 receptor agonist (peptide analogue)
Developer
Novo Nordisk
Molecular weight
~4,114 Da
Molecular formula
C187H291N45O59
PubChem CID
56843331
Homology to native GLP-1
~94%
Half-life
About one week
Brands
Ozempic, Wegovy, Rybelsus

What was changed from the natural hormone

Native GLP-1 has a half-life of one to two minutes, which makes it useless as a medicine. Semaglutide makes three changes. Alanine at position 8 is replaced with α-aminoisobutyric acid (Aib), which DPP-4 cannot cleave. Lysine 26 carries a C18 diacid chain attached through a γGlu-2xOEG linker, which binds reversibly to serum albumin and shields the peptide from renal clearance. Arginine 34 is substituted for lysine so the fatty acid attaches at a single defined site. The result is a half-life of about a week.

How albumin binding actually extends half-life

This is worth understanding because the same trick appears in liraglutide, retatrutide and most modern incretin analogues. Albumin is a large, abundant, long-lived plasma protein. A peptide bound to it is too large for glomerular filtration and is physically shielded from proteases. Because binding is reversible, a small free fraction remains available to engage the receptor at any moment, and the albumin-bound pool acts as a slow-release depot. Chain length tunes the effect: liraglutide's C16 chain gives roughly a day, semaglutide's C18 diacid gives about a week.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The three products and why they differ

Ozempic is semaglutide for type 2 diabetes, injected weekly. Wegovy is the same molecule at higher dose for weight management. Rybelsus is oral semaglutide, co-formulated with the absorption enhancer SNAC and taken daily with dosing conditions (a fasting window and a defined water volume), because a peptide cannot otherwise survive the stomach.

SELECT and cardiovascular outcomes

The SELECT trial enrolled 17,604 participants aged 45 or over with a BMI of 27 or above, established cardiovascular disease and no diabetes, across 41 countries. Semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% against placebo, published in the New England Journal of Medicine in 2023. This mattered because it moved the class from weight reduction as an endpoint in itself to demonstrated hard-outcome benefit.

Where it sits now

Semaglutide is no longer the most effective incretin available (SURMOUNT-5 showed tirzepatide producing substantially greater reduction head-to-head), but it has by far the largest outcome-trial evidence base, and additional indications including heart failure with preserved ejection fraction and peripheral artery disease have been under regulatory review.

Frequently asked questions

Is semaglutide the same as Ozempic and Wegovy?

Yes, it is the same molecule. The brands differ by indication and dose: Ozempic for type 2 diabetes, Wegovy for weight management, Rybelsus as the oral formulation.

Why does semaglutide only need weekly dosing?

The Aib8 substitution blocks DPP-4 cleavage and the C18 diacid chain binds albumin, which together extend the half-life from minutes to about a week.

What does 94% homology mean?

That the sequence is nearly identical to human GLP-1. The differences are a small number of deliberate substitutions plus the fatty-acid attachment.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.